Pediatrix Medical Group, Inc. (NYSE:MD) Receives Average Recommendation of “Hold” from Brokerages

Pediatrix Medical Group, Inc. (NYSE:MD) has been given a consensus rating of “Hold” by the six brokerages that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $21.00.

A number of brokerages have issued reports on MD. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. Zacks Research downgraded Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Truist Financial upped their price objective on Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. Finally, UBS Group raised their target price on Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th.

Insiders Place Their Bets

In other Pediatrix Medical Group news, CEO Mark S. Ordan sold 23,000 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.41, for a total value of $515,430.00. Following the completion of the transaction, the chief executive officer owned 302,805 shares in the company, valued at approximately $6,785,860.05. This represents a 7.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MD. Global Retirement Partners LLC boosted its position in Pediatrix Medical Group by 68,250.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock worth $29,000 after acquiring an additional 1,365 shares during the period. Transamerica Financial Advisors LLC acquired a new position in Pediatrix Medical Group during the 4th quarter valued at about $30,000. Eurizon Capital SGR S.p.A. bought a new position in shares of Pediatrix Medical Group in the fourth quarter valued at approximately $33,000. Blue Trust Inc. bought a new stake in Pediatrix Medical Group during the fourth quarter worth approximately $37,000. Finally, TD Private Client Wealth LLC acquired a new stake in Pediatrix Medical Group in the fourth quarter worth approximately $39,000. 97.71% of the stock is owned by institutional investors.

Pediatrix Medical Group Stock Up 1.1%

MD stock opened at $21.96 on Thursday. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of 11.56 and a beta of 0.76. Pediatrix Medical Group has a 1-year low of $11.84 and a 1-year high of $24.99. The firm has a fifty day moving average price of $21.69 and a two-hundred day moving average price of $19.51. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.83 and a quick ratio of 1.83.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.